Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2022.2253
Abstract: Key Points Question Does the addition of apatinib, a vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor, to treatment with pegylated liposomal doxorubicin (PLD) improve progression-free survival in patients with platinum-resistant recurrent ovarian cancer?… read more here.
Keywords: pegylated liposomal; recurrent ovarian; platinum resistant; liposomal doxorubicin ... See more keywords
Resistant and Recurrent Late Reaction to Hyaluronic Acid-Based Gel.
Sign Up to like & getrecommendations! Published in 2017 at "Dermatologic Surgery"
DOI: 10.1097/dss.0000000000000880
Abstract: As the popularity of soft-tissue fillers increases, strategies to prevent complications are increasingly sought. Blindness ranks among the most serious and rare of these complications; the cause remains unknown, but is predominantly believed to result… read more here.
Keywords: acid based; resistant recurrent; reaction hyaluronic; late reaction ... See more keywords
Apatinib plus paclitaxel versus paclitaxel monotherapy for platinum‐resistant recurrent ovarian cancer treatment: A retrospective cohort study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1111/jcpt.13806
Abstract: Apatinib, an oral antiangiogenic drug, exerts potential anti‐tumour effects on platinum‐resistant recurrent ovarian cancer (PROC). This study intended to evaluate the efficacy and safety of apatinib plus paclitaxel compared to paclitaxel monotherapy in PROC patients. read more here.
Keywords: recurrent ovarian; platinum resistant; ovarian cancer; apatinib plus ... See more keywords
Surgery in platinum-resistant recurrent epithelial ovarian carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "World Journal of Clinical Cases"
DOI: 10.12998/wjcc.v10.i12.3739
Abstract: BACKGROUND Ovarian cancer is one of the three most common malignant tumors of the female reproductive tract and ranks first in terms of mortality among gynecological tumors. Epithelial ovarian carcinoma (EOC) is the most common… read more here.
Keywords: surgery; resistant recurrent; eoc; platinum resistant ... See more keywords
REBECA trial: a new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer
Sign Up to like & getrecommendations! Published in 2020 at "Translational cancer research"
DOI: 10.21037/tcr.2019.12.83
Abstract: Lee et al . (1) evaluated the efficacy and safety of bevacizumab in combination with single-agent chemotherapy for platinum-resistant ovarian cancer in a large retrospective analysis involving Korean women with platinum-resistant recurrent ovarian cancer from… read more here.
Keywords: bevacizumab; resistant recurrent; ovarian cancer; platinum resistant ... See more keywords